MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-022-10083-8

Медицинская библиотека · BMC cancer · 2022

Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.

Chen Zhengting, Zhou Lingli, Zhao Min, Cao Ke, Li Yanqing, Liu Xiaoling, Hou Yu, Li Lan, Wang Li, Chang Li, Yang Mei, Li Wenhui, Xia Yaoxiong

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Stereotactic radiosurgery (SRS) has become a standard approach for the treatment of patients with few metastatic brain lesions. However, the optimal treatment approach for the use radiotherapy in the treatment of non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) remain unclear. This study aimed to compare the survival outcomes and intracranial local control in NSCLC patients with 1-4 BMs who are treated with SRS using linear accelerators (LINAC-SRS), whole-brain radiotherapy (WBRT), or WBRT plus radiotherapy boost (WBRT + RTB).

MATERIALS AND

METHODS

We retrospectively analyzed 156 NSCLC patients with 1-4 BMs who received LINAC-SRS, WBRT, and WBRT + RTB. The median overall survival (OS), intracranial progression-free survival (iPFS), and distant brain failure-free survival (DBF-FS) and related prognostic factors were analyzed.

RESULTS

The median follow-up period was 31.6 months. The median OS times in the LINAC-SRS, WBRT, and WBRT + RTB groups were not reached, 33.3 months and 27.9 months, respectively. The difference in survival rate was non-significant (P = 0.909). The 2-year iPFS and DBF-FS rates in the LINAC-SRS, WBRT and WBRT + RTB groups were 51.6% and 37.5%; 42.0% and 50.4%; and 51.1% and 56.1%, respectively. There was no significant difference in 2-year iPFS or DBF-FS among the three groups (P = 0.572 for iPFS, P = 0.628 for DBF-FS). Multivariate analysis showed that the independent adverse prognostic factors for OS, iPFS, and DBF-FS were neurological symptoms, recursive partitioning analysis (RPA) class, and targeted therapy.

CONCLUSION

LINAC-SRS did not result in significantly superior survival times or intracranial local control compared to WBRT or WBRT + RTB in the treatment of NSCLC patients with 1-4 BMs.

Для цитирования: Chen Zhengting, Zhou Lingli, Zhao Min, Cao Ke, Li Yanqing, Liu Xiaoling, Hou Yu, Li Lan, Wang Li, Chang Li, Yang Mei, Li Wenhui, Xia Yaoxiong. Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.. BMC cancer. 2022. DOI: 10.1186/s12885-022-10083-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.